2019
DOI: 10.1016/j.thromres.2019.01.001
|View full text |Cite
|
Sign up to set email alerts
|

Association between SLC44A2 rs2288904 polymorphism and risk of recurrent venous thromboembolism among Thai patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
15
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(15 citation statements)
references
References 9 publications
0
15
0
Order By: Relevance
“…Using transcriptomic and proteomic data, we identified 30 transmembrane candidates that were preferentially expressed in neutrophils (or T-cells) over monocytes. From this list, SLC44A2 stood out due to its recent identification as a risk locus for both VTE and stroke, but with as yet unknown functional association with these pathologies (Apipongrat et al, 2019;Germain et al, 2015;Hinds et al, 2016). As plateletleukocyte interactions are involved in both of these thrombotic disorders, we hypothesized that SLC44A2 functions as the neutrophil counter receptor for activated α IIb β 3 .…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Using transcriptomic and proteomic data, we identified 30 transmembrane candidates that were preferentially expressed in neutrophils (or T-cells) over monocytes. From this list, SLC44A2 stood out due to its recent identification as a risk locus for both VTE and stroke, but with as yet unknown functional association with these pathologies (Apipongrat et al, 2019;Germain et al, 2015;Hinds et al, 2016). As plateletleukocyte interactions are involved in both of these thrombotic disorders, we hypothesized that SLC44A2 functions as the neutrophil counter receptor for activated α IIb β 3 .…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, alternative targets that inhibit DVT disease processes, but that do not modify bleeding risk may provide new adjunctive therapies to further protect against the development or recurrence of DVT. GWAS studies have also identified additional risk loci for VTE, but with no known role in coagulation (Apipongrat et al, 2019;Germain et al, 2015;Hinds et al, 2016). This provides encouragement that alternative therapeutic targets may exist with the potential to modify the disease process without affecting bleeding risk.…”
Section: Introductionmentioning
confidence: 96%
See 1 more Smart Citation
“…Therefore, alternative targets that inhibit DVT disease processes, but that do not modify bleeding risk may provide new adjunctive therapies to further protect against the development or recurrence of DVT. GWAS studies have also identified additional risk loci for VTE, but with no known role in coagulation (Apipongrat et al, 2019;Germain et al, 2015;Hinds et al, 2016). This provides encouragement that alternative therapeutic targets may exist with the potential to modify the disease process without affecting bleeding risk.…”
Section: Introductionmentioning
confidence: 99%
“…This provides encouragement that alternative therapeutic targets may exist with the potential to modify the disease process without affecting bleeding risk. These loci include SLC44A2 and TSPAN15 genes (Apipongrat et al, 2019;Germain et al, 2015;Hinds et al, 2016). Despite the identification of these loci, the function of these cell surface proteins with respect to their involvement in the pathogenesis of venous thrombosis remains unclear.…”
Section: Introductionmentioning
confidence: 99%